Oligometastatic NSCLC: Current Evidence and Future Directions
There are phase II randomized trials that show a benefit to local consolidative SBRT in oligometastatic non-small cell lung cancer. There are pending phase III trials that have not yet read out. This leaves questions to practioners as to how to best treat oligometastatic non-small cell lung cancer in the real world setting.
There are emerging strategies examining biomarkers that may be able to identify oligometastatic patients who will benefit from local consolidative therapy.
This meeting is designed to meet the interests of medical oncologists, radiation oncologists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists and pulmonologists.
Upon completion of this activity, participants should be able to do the following:
- Understand the clinical trial landscape around oligometastatic NSCLC and which trials will result soon.
- Understand emerging biomarkers in the oligometastatic NSCLC space.
- Kristin Higgins, MD
- Daniel Gomez, MD, MBA
- Puneeth Iyengar, MD
A list of all meeting faculty and Individual presenter disclosures are linked to their names in the Schedule of Events.
A list of all meeting planning committee members and their individual disclosures can be found on the Planning Committee website page.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 0.75 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 0.75 Certificate of AttendanceThis activity was designated for 0.75 AMA PRA Category 1 Credit™.